Table 2.
Clinical characteristics, results at the baseline visit and of the first post-conization control performed at six months, and HPV genotype at the end of follow-up in the vaccinated and non-vaccinated women who showed persistent/recurrent HSIL at the end of follow-up.
| Case Number | Age | Indication of Conization | Pre-Treatment HPV Genotype | Conization Diagnosis | Cone Margins | First Post-Conization Control Result (6 Months) | HPV Genotype at the End of Follow-Up | Vaccine Type | Doses |
|---|---|---|---|---|---|---|---|---|---|
| Vaccinated women who showed persistent/recurrent HSIL (n = 5) | |||||||||
| 1 | 38.2 | HSIL/CIN 2–3 | HPVnon16/non18 | LSIL/CIN1 | Positive | Persistent LSIL/HPV | HPVnon16/non18 | Unknown | 3 |
| 2 | 41.2 | Pap HSIL, biopsy LSIL/CIN1 | HPVnon16/non18 | HSIL/CIN2 | Negative | Persistent LSIL/HPV | HPVnon16/non18 | 2v | 3 |
| 3 | 41.6 | HSIL/CIN 2–3 | HPVnon16/non18 | LSIL/CIN1 | Positive | Persistent LSIL/HPV | HPVnon16/non18 | 9v | 3 |
| 4 | 30.7 | HSIL/CIN 2–3 | HPV16 | HSIL/CIN2 | Positive | Persistent LSIL/HPV | HPV16 | 9v | 3 |
| 5 | 46.5 | Pap HSIL, biopsy LSIL/CIN1 | HPV16 | Negative | Negative | Persistent HSIL/CIN2-3 | HPV16 | 9v | 2 |
| Non-vaccinated women who showed persistent/recurrent HSIL (n = 12) | |||||||||
| 6 | 31.1 | HSIL/CIN 2–3 | HPVnon16/non18 | HSIL/CIN2 | Negative | No disease | HPV16 | - | - |
| 7 | 64.2 | HSIL/CIN 2–3 | HPVnon16/non18 | HSIL/CIN2 | Negative | Persistent LSIL/HPV | HPVnon16/non18 | - | - |
| 8 | 41.6 | Pap HSIL, biopsy LSIL/CIN1 | HPV16 | LSIL/CIN1 | Positive | Persistent LSIL/HPV | HPV16 | - | - |
| 9 | 45.4 | HSIL/CIN 2–3 | HPV16 | HSIL/CIN3 | Negative | No disease | HPVnon16/non18 | - | - |
| 10 | 33.0 | HSIL/CIN 2–3 | HPV18 | HSIL/CIN2 | Negative | No disease | HPVnon16/non18 | - | - |
| 11 | 66.2 | HSIL/CIN 2–3 | HPV16 | HSIL/CIN3 | Negative | Persistent LSIL/HPV | HPVnon16/non18 | - | - |
| 12 | 39.9 | HSIL/CIN 2–3 | HPVnon16/non18 | HSIL/CIN3 | Negative | No disease | HPVnon16/non18 | - | - |
| 13 | 33.2 | HSIL/CIN 2–3 | HPV16 | HSIL/CIN2 | Positive | Persistent LSIL/HPV | HPV16 | - | - |
| 14 | 50.4 | HSIL/CIN 2–3 | HPVnon16/non18 | Negative | Negative | Persistent LSIL/HPV | HPVnon16/non18 | - | - |
| 15 | 61.4 | Pap HSIL, biopsy LSIL/CIN1 | HPVnon16/non18 | LSIL/CIN1 | Negative | Persistent HSIL/CIN2-3 | HPVnon16/non18 | - | - |
| 16 | 54.9 | HSIL/CIN 2–3 | HPV16 | LSIL/CIN1 | Negative | Persistent HSIL/CIN2-3 | HPV16 | - | - |
| 17 | 26.8 | HSIL/CIN 2–3 | HPV16 | HSIL/CIN2 | Positive | Persistent LSIL/HPV | HPV16 | - | - |
HPV: human papillomavirus. LSIL: low-grade squamous intraepithelial lesion; HSIL: high-grade squamous intraepithelial lesion; CIN1: cervical intraepithelial neoplasia grade 1; CIN2: CIN grade 2; 9v: nine-valent vaccine; 2v: bivalent vaccine.